CV-6209

Research use only, not for human use.

A highly potent, selective platelet activating factor (PAF) inhibitor with IC50 of 75 and 170 nM for aggregation inhibition of rabbit and human platelets induced by PAF.

A highly potent, selective platelet activating factor (PAF) inhibitor with IC50 of 75 and 170 nM for aggregation inhibition of rabbit and human platelets induced by PAF; shows little to no effects on the aggregation induced by arachidonic acid, ADP and collagen; inhibited PAF-induced hypotension in rats (ED50=0.009 mg/kg i.v.) with no effect on the hypotension induced by arachidonic acid, histamine, bradykinin and isoproterenol.Ulcer Discontinued.

CV-6209 inhibits [3H]serotonin release from rabbit platelets stimulated with PAF (30 nM).CV-6209 has little action on platelet aggregation induced by arachidonic acid, ADP, or collagen.CV-6209 (0.2-2 μM; pretreated for 30 min) inhibits PAF-induced MC degranulation in both LAD2 and hLMCs.

CV-6209 (i.v.) inhibits PAF (0.3 μg/kg; i.v.)-induced hypotension in rats (ED50=0.009 mg/kg) with no effect on the hypotension induced by arachidonic acid, histamine, bradykinin and isoproterenol.CV-6209 (66 μg; i.v.) reduces asparaginase-induced hypersensitivity compared with nonpretreated, sensitized mice.

CV 6209 | CV6209

GPCR/G Protein

Platelet-activating Factor Receptor

Platelet-activating Factor Receptor

Other Indications

Ulcer

100488-87-7

642.3

C34H60N3O6Cl

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (155.69 mM)

O=C(OCC(OC)COC(N(C(C)=O)CC1=CC=CC=[N+]1CC)=O)NCCCCCCCCCCCCCCCCCC

2-[N-acetyl-N-(2-methoxy-3-octadecylcarbamoyloxypropoxycarbonyl) aminomethyl]-1-ethylpyridinium chloride

(-20℃)

With Ice Pack

≥ 2 years